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Vaccine Administered to Adults 55 Years of Age and Older
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Connaught, Lyon, and Pasteur Me´rieux Connaught,Georges Holla¨nder, Fabrice Bailleux, Christophe Rudin,
Marnes-la-Coquette, Franceand Herve´ Creusvaux
Decreased cell-mediated immune (CMI) response to varicella-zoster virus (VZV) is correlated
with an increased risk of reactivation of latent virus from dorsal root sites, leading to herpes zoster.
The cell-mediated and humoral immunogenicity of three concentrations (3200, 8500, and 41,650
pfu/dose) of a live attenuated VZV vaccine (Oka strain; VZV/Oka) was compared with a control
pneumococcal polysaccharide vaccine in 200 healthy adults who were ⁄55 years old. Six weeks
after vaccination, the VZV-specific CMI response (as measured by stimulation index values and
precursor cell frequencies) was enhanced in all VZV/Oka vaccine groups compared with the control
group (for all VZV/Oka groups combined vs. controls, tested with VZV crude antigen: stimulation
index, P  .001; precursor cell frequency, P  .001). Geometric mean titers of anti-VZV antibodies
increased in all VZV/Oka vaccine groups but remained unchanged in the control vaccine group.
No dose effect of VZV/Oka vaccine was observed for CMI or humoral responses.
Herpes zoster is a painful cutaneous eruption caused by decrease the severity of zoster episodes [6]. Of note, none of
these previous studies included a control group.reactivation of latent varicella-zoster virus (VZV), the agent
that causes chickenpox in children. It is estimated that over a Vaccination with live attenuated VZV vaccine thus repre-
sents a potential strategy for preventing zoster and/or pre-lifetime,15% of persons who experienced clinical or subclin-
ical varicella infection will eventually develop zoster [1]. Her- venting or lessening zoster-associated pain in persons who may
already harbor latent VZV [7]. This randomized, controlledpes zoster may be associated with severe neurologic manifesta-
tions and complications, mainly acute pain and postherpetic trial in 200 healthy older adults evaluated the cell-mediated
and humoral immunogenicity and the safety of one of threeneuralgia.
The risk of developing herpes zoster is inversely correlated to doses of a live attenuated VZV/Oka vaccine compared with a
control vaccine.the status of VZV-specific cell-mediated immunity. Progressive
loss of cell-mediated immunity is a natural part of the aging
process and is correlated with an increase of zoster incidence Materials and Methods
and more severe zoster complications (e.g., postherpetic neural-
Study population. Healthy adults were enrolled in this studygia and ophthalmic zoster) [1–3].
during routine out-patient visits. The main inclusion criteria wereEnhancement of the VZV-specific immune response of
age⁄55 years, previous history of varicella confirmed by positivehealthy adults by immunization with a live attenuated VZV
serology to VZV (screened using Enzygnost; Behringwerke, Mar-
vaccine (Oka strain; VZV/Oka) was first demonstrated by
burg, Germany), and a competent immune system (no signs of
Berger et al. [4]. Subsequently, these results were confirmed immunodeficiency). Main exclusion criteria were fever at the time
by Levin et al. [5], who immunized a cohort of 202 healthy of selection, any previous zoster episode, seropositivity to human
older subjects (⁄55 years) with one or two doses of a live immunodeficiency virus (screened using Genelavia mixt; Sanofi
attenuated VZV/Oka vaccine at different concentrations (1140 Diagnostics Pasteur, France), any underlying immunodepressive
condition, previous vaccination against varicella or zoster, anyto 12,040 pfu/dose) and demonstrated that both humoral and
other recent vaccination, recent administration of any blood prod-cell-mediated VZV immunity could be boosted by active im-
uct, and sensitivity to neomycin.munization with VZV/Oka. Moreover, the 4-year follow-up
Study design. Study participants were randomly assigned to 1of this cohort suggested that vaccination with VZV/Oka may
of 4 vaccine groups. Three groups received a subcutaneous injec-
tion of a live attenuated VZV/Oka vaccine [8] manufactured by
Pasteur Me´rieux Connaught (Lyon). Patients in these groups were
randomly allocated one of three concentrations (3200, 8500, orInformed consent was obtained from all subjects who participated in this
41,650 pfu/dose) of live VZV/Oka under double-blind conditions.study. The trial was approved by the Ethics Committee of the University
Hospital, Basel, Switzerland. The fourth group was vaccinated subcutaneously with a licensed
Financial support: Pasteur Me´rieux Connaught, Lyon, France. pneumococcal polysaccharide vaccine (Pneumo 23, lot L0042;
Reprints or correspondence: Dr Herve´ Creusvaux, Pasteur Me´rieux Con-
Pasteur Me´rieux Connaught, Lyon; distributed in France by Pasteurnaught, 3 ave. Pasteur, B.P. 10, 92430 Marnes-la-Coquette, France.
Me´rieux Se´rums et Vaccins, Marnes-la-Coquette). This vaccine
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was administered under single-blind conditions and was used asq 1998 by the Infectious Diseases Society of America. All rights reserved.
0022–1899/98/78S1–0022$02.00 a control for reactogenicity and immune response.
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Vaccine recipients noted the occurrence of any adverse reactions Table 1. Percentage of subjects (n  200) with local adverse reac-
tions during 6 weeks after vaccination with Oka VZV/Oka vaccine,to vaccination in individual monitoring diaries and were followed
according to vaccine group.by means of medical visits at days 3 and 42 after vaccination. If
vesicular rash or zoster occurred, subjects returned to the study
VZV/Oka vaccinecenter for an additional medical visit, and vesicles were sampled
for VZV identification by polymerase chain reaction (PCR) and
3200 8500 41,650 Pneumo 23*
restriction analysis [9]. Injection-site reaction pfu pfu pfu vaccine
Vaccine. The Pasteur Me´rieux Connaught VZV/Oka vaccine
is freeze-dried and has been demonstrated to have good stability None 60.0 58.8 73.5 34.0
for at least 2 years at 57C [10]. The vaccine should be reconstituted ⁄1 reaction 40.0 41.2 26.5 66.0
Induration (diameter ⁄2 cm) 18.0 21.6 8.2 16.0with diluent (NaCl, 4 g/L) immediately before subcutaneous injec-
Pain (all) 28.0 37.2 24.5 58.0tion. Three lots corresponding to the three concentrations were
Pain (probably vaccine related) 14.0 19.0 12.0 29.0used for the study: S2885, 3200 pfu/dose; S2887, 8500 pfu/dose;
Redness (diameter ⁄2 cm) 26.0 17.6 12.2 26.0and S3061, 41,650 pfu/dose. These concentrations of VZV/Oka
Pruritus 10.0 7.8 8.2 6.0vaccine were chosen in order to obtain widely differing virus titers
Vesicle 0 2.0 0 0
between the 3 groups (i.e., a difference of at least 0.3 in log10
plaque-forming units [pfu]). The control, a purified polyvalent * Pneumococcal polysaccharide vaccine (licensed by Pasteur Me´rieux Con-
Streptococcus pneumoniae polysaccharide liquid vaccine, was ad- naught, Lyon, France, and distributed in France by Pasteur Me´rieux Se´rums
et Vaccins, Marnes-la-Coquette).ministered subcutaneously.
Assays for VZV immunity. Blood samples were obtained for
the measurement of cell-mediated immune (CMI) and humoral
immune responses before and 42 days after vaccination. was taken to be 500/106 cells. After log10 transformation, geometric
T cell recognition of VZV antigen was determined by incubating means of the SI and PCF were calculated for each vaccine group.
peripheral blood mononuclear cells (105/well) with dilutions of Since statistical tests did not reject the homogeneity of the regres-
inactivated crude VZV antigen (Pasteur Me´rieux Connaught, sion lines for pre- and postvaccination responses between the 4
Lyon), purified VZV glycoproteins (Viro Research, Rockford, IL), vaccine groups (slope test: P ⁄ .184 for SI and PCF), data were
purified VZV immediate early protein 62 (IE62; Viro Research), analyzed by use of a covariance analysis model. This statistical
and MRC-5 substrate antigens (negative control) and tetanus tox- procedure enabled adjustment for prevaccination values. The fol-
oid (positive control) (Pasteur Me´rieux Connaught, Lyon) in RPMI lowing comparisons were made: all VZV/Oka vaccine groups
medium with 10% human serum for 6 days [5, 11]. The inactivated against control, highest dose of VZV/Oka vaccine against control,
VZV crude antigen and MRC-5 antigen were each prepared at and trend effect for the different VZV/Oka doses (dose response).
protein concentrations of 3.5 mg/mL. All antigen dilutions were Contrasts were done at the 2.5% level of significance, adjusting
made with lymphocyte culture medium. Optimal antigen concen- for three related contrasts.
trations in cultures were 1:3000 of the initial solution for inacti-
vated VZV crude antigens and MRC-5 antigen (precise quantita-
tion of antigen was not possible), 417 ng/mL for VZV Results
glycoproteins, 167 ng/mL for IE62, and 50 mg/mL for tetanus
toxoid. Proliferation was detected by [3H-methyl]thymidine uptake Study population. Two hundred older adult subjects (age
during 6 h of incubation. range, 55–88 years), comprising 82 women and 118 men, were
The stimulation index (SI) was calculated as the ratio of the enrolled in the trial. Slightly fewer women (34%) and a higher
mean counts per minute (cpm) in antigen-specific stimulated wells mean age (67.7 years) were found in the 3200-pfu VZV/Oka
to the mean cpm in the respective negative control wells. Four
vaccine group compared with the other groups (women, 41%–
replicates per measurement were performed.
45%; mean age, 64.7–65.2 years); however, the higher age inThe precursor cell frequency (PCF) analysis was done by use
this group can be explained by the advanced age (77 and 88of the limiting dilution culture as described by Levin et al. [5] and
years) of 2 members. Although a possible potential selectionHayward et al. [11], except that cultures were incubated for 6
bias cannot be ruled out, between-group differences wererather than 10 days. PCF was expressed as the number of VZV
antigen–specific cells per 106 lymphocytes. mostly likely random, and the age and gender distributions
Humoral immune response. Determination of IgG antibodies were not considered different among the 4 groups.
to VZV were measured before vaccination and 6 weeks after vacci- Reactogenicity and safety. Adverse reactions observed dur-
nation (day 42) using an in-house glycoprotein ELISA [12] at ing the 6 weeks following vaccination are summarized in table
Pasteur Me´rieux Connaught (Laboratoire Se´ro-Immuno Clinique, 1. Overall, the VZV/Oka vaccine was well tolerated compared
Val de Reuil, France).
with the pneumococcal polysaccharide control vaccine. At least
Data analysis. Data were dual entered in database software
one adverse reaction was experienced by 26.5%–41.2% of the(Climed; Simed, Cre´teil, France). Statistical analysis was done by
subjects in the groups that received one of the doses of thethe Biometry Department of Pasteur Me´rieux Connaught (Marnes-
VZV/Oka vaccine, compared with 66% of subjects who re-la-Coquette) using SAS software (SAS Institute, Cary, NC); SI
ceived the control vaccine. Pain at the injection site that wasvalues and PCFs were estimated before vaccination and at day 42.
For the purposes of analysis, the PCF at the upper limit of detection judged by the investigator to be probably related to the vaccine
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was reported less frequently after VZV/Oka vaccination (12%– in all VZV/Oka vaccine groups and remained unchanged in
the pneumococcal polysaccharide control vaccine group. The19% of subjects) than after the pneumococcus control vaccina-
tion (29%). Incidences of redness, pruritus, and induration were geometric mean titer ratios (day 42/before vaccination) and
95% CIs were 1.4 (95% CI, 1.2–1.7), 1.4 (95% CI, 1.2–1.7),no more frequent in the VZV/Oka groups than in the control
group. and 1.3 (95% CI, 1.2–1.7) in the 3200-pfu, 8500-pfu, and
41,650-pfu groups, respectively, compared with 1.0 (95% CI,No subject had a fever during the 72 h following vaccination.
One subject in the 8500-pfu VZV/Oka group presented with a 0.9–1.1) in the control group. Increases were significant in all
VZV/Oka groups (lower boundary of 95% CIs, 1.0), but notmild vesicular rash at the injection site (10 vesicles) that
occurred 1 day after vaccination and lasted 7 days. PCR analy- in the control group (lower boundary of 95% CIs, 1.0).
A correlation analysis revealed that the antibody responsesis of the vesicular fluid was negative for VZV.
CMI response to VZV. Analysis of the geometric mean of was not correlated with the SI response, irrespective of the
VZV antigen used (r  .05, Pearson’s correlation coefficient).SI values showed that the VZV antigen–specific proliferative
response was significantly enhanced in all VZV/Oka vaccine
groups after vaccination but remained unchanged in the control
Discussion
group. On day 42, the mean proliferative responses in the
groups receiving VZV/Oka vaccine, adjusting for prevaccina- The results from this randomized, controlled study confirmed
previous observations in uncontrolled trials that vaccinationtion titers, were 5.62–7.24 for crude VZV antigen (vs. 2.88 in
the controls), 2.29–3.09 for purified VZV glycoproteins (vs. with live attenuated VZV/Oka vaccine is safe and enhances
CMI to VZV in older adult subjects [4, 5]. The VZV/Oka1.41 in controls), and 1.38–1.58 for IE62 (vs. 1.05).
SI ratios (day 42/before vaccination) and 95% confidence vaccine used in this study was well tolerated, and vaccinated
subjects presented few local and general reactions, even withintervals (95% CIs) were 1.6 (95% CI, 1.1–2.2), 1.5 (95% CI,
1.1–2.1), and 2.5 (95% CI, 1.9–3.3) in the 3200-pfu, 8500- the highest dose of VZV/Oka vaccine used (41,650 pfu). In
fact, the incidence of local reactions was lower in the grouppfu, and 41,650-pfu groups, respectively, compared with 0.85
(95% CI, 0.6–1.2) in the control group. A covariance analysis of subjects who received the highest dose of VZV/Oka vaccine
(26.5%) compared with the other 2 VZV/Oka groups (3200model with prevaccination SI values as covariables did not
detect any statistically significant dose effect for the different pfu, 40.0%; 8500 pfu, 41.2%), although these differences were
not tested statistically. In particular, induration was reportedVZV/Oka concentrations in the CMI response to VZV, as mea-
sured by the adjusted geometric mean SI at day 42 (trend test less frequently in the 41,650-pfu group (8.2% compared with
18.0%–21.6%), and redness tended to decrease as the vaccinenot significant for any VZV antigen: trend effect P ⁄ .177).
Nonetheless, considering all VZV/Oka groups together, ad- dose increased (26.0%–12.2%). The reason for these descrip-
tive differences between the different doses of VZV/Oka vac-justed geometric mean SI values were statistically significantly
higher after VZV/Oka vaccination than control vaccination for cine is not clear but might be due to chance or other unknown
factors, since the safety evaluation was done under double-all VZV antigens (P  .001, crude VZV; P  .001, VZV
glycoproteins; P  .003, IE62). blind conditions. Of importance, the local reactogenicity of
each dose of VZV/Oka was better than that of the widely usedThe PCFs before and after (day 42) vaccination are presented
in figure 1. Geometric mean PCF (per 106 cells) increased after pneumococcal polysaccharide control vaccine.
To our knowledge, this is the first time such a high vaccinevaccination in all VZV/Oka groups but remained unchanged
in the control group. Increases in geometric mean PCFs (per dose (41,650 pfu) has been administered to VZV-seropositive
subjects, and it confirms the innocuous nature of the VZV/106 cells) from before vaccination to day 42 were as follows
for the different VZV/Oka doses: from 52.5 to 89.1 in the Oka strain. Only 1 subject (in the 8500-pfu group) presented
postvaccination vesicles (10), which might have been caused3200-pfu group, from 37.2 to 91.2 in the 8500-pfu group, and
from 22.4 to 66.1 in the 41,650-pfu group. In the control group, by the vaccine; however, the vesicles were VZV-negative as
determined by PCR analysis of vesicular fluid. No subject pre-the geometric mean PCF decreased slightly from 37.2 before
vaccination to 26.9 at day 42. This very small decrease does sented any varicella-like rash or zoster during the 6-week fol-
low-up.not appear related to the pneumococcal polysaccharide control
vaccine since the same effect was also observed with the con- All in vitro measurements of cell-mediated immunity (SI
and PCF) and VZV glycoprotein–specific antibody titers weretrol tetanus toxoid antigen (data not shown). After adjustment
for prevaccination PCFs, no statistically significant dose effect significantly increased 6 weeks after vaccination (day 42) in
the 3 VZV/Oka groups, compared with the control group. Thewas found for the different VZV/Oka doses in the geometric
mean PCF at day 42. Still, the adjusted geometric mean PCF adjusted geometric means for SI values at day 42 were about
two times higher in the VZV/Oka groups compared with thewas statistically significantly higher when all VZV/Oka groups
together were compared against the control group. control group, and, likewise, adjusted geometric mean PCFs
were approximately three times higher in the active vaccineHumoral immune response. After vaccination, geometric
mean titer values of antibodies to VZV glycoproteins increased groups. Results were consistent for all VZV antigens, but, as
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Figure 1. Individual precursor cell frequencies (PCFs; no./106 cells) in 4 groups of subjects before (PRE) and 42 days after (D42) vaccination
with various doses (in plaque-forming units) of Oka strain of VZV or with Pneumo 23 (pneumococcal polysaccharide vaccine; Pasteur Me´rieux
Connaught, Lyon, France; distributed in France by Pasteur Me´rieux Se´rums et Vaccins, Marnes-la-Coquette). Solid horizontal bars  geometric
mean PCFs.
expected, crude VZV antigen elicited the best proliferative Although prevaccination VZV antibody titers tended to be
high in the subjects, this did not prevent vaccination with VZV/response. Proliferative response to purified IE62 VZV antigen
was observed only in a minority of vaccinees, and all of these Oka from boosting the CMI and humoral immune responses.
Six weeks after vaccination with VZV/Oka vaccine, VZV-responders to IE62 demonstrated a proliferative response to
VZV glycoproteins. Furthermore, all responders to VZV glyco- antibody levels had increased by30%–40%, and a significant
proliferative response was obtained. No boost of VZV glyco-proteins demonstrated a response to crude VZV antigen.
protein–specific antibodies or CMI response was seen in theSix weeks after vaccination, there were no significant differ-
control group.ences in VZV-specific immune responses between the different
virus concentrations tested. This indicated that either the lowest The vaccine concentrations tested were selected on the basis
of infectivity titer (pfu/dose), not on the inactive viral antigen.dose (3200 pfu) is sufficient to boost the CMI or that other
inactive viral components of the VZV/Oka preparation used The three concentrations were chosen to obtain significantly
different pfu contents per dose, according to the accuracy ofmay compensate for the lower pfu content by additionally en-
hancing the immune response [13]. As previously reported by the plaque assay. On the basis of our data, the lowest dose of
VZV/Oka vaccine (3200 pfu) is sufficient to significantly boostLevin et al. [5], the VZV CMI response early after vaccination
was not related to the dose of the vaccine given. However, a both CMI and antibody response to VZV.
difference may appear between doses after several years of A long-term follow-up of the vaccinated subjects is being
follow-up, with a longer-lasting enhancement of immune re- conducted both to determine whether the enhanced VZV-spe-
sponse being obtained with high vaccine doses [6]. Further cific CMI response obtained after a single vaccination with
long-term assessment of CMI and humoral response after vacci- VZV/Oka is long lasting and also to monitor the zoster inci-
dence. It is not known whether a boost of VZV cell-mediatednation with VZV/Oka vaccine will be needed to confirm this
latter finding. immunity will protect against the occurrence of zoster or, as
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4. Berger R, Luescher D, Just M. Enhancement of varicella-zoster–specificseems more likely, will lessen the severity of a zoster episode
immune responses in the elderly by boosting with varicella vaccine. J[6, 7]. A large, double-blind, placebo-controlled trial is needed
Infect Dis 1984;149:647.
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